ASCO 2017 | Is pembrolizumab alone sufficient to treat bladder cancer?
Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute, London, UK, talks to us about the positive results obtained from a Phase III trial involving the treatment of bladder cancer patients who failed to respond to chemotherapy, with pembrolizumab (NCT02628067). He hopes that the use of single-agent pembrolizumab will be sufficient to produce a long-term durable response in patients and notes that there are good clinical data supporting this, and on atezolizumab. If successful, this new regimen may reduce the need for chemotherapy in cancer patients in the future. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
Get great new content delivered to your inboxSign up